MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
BeOne Medicines, formerly, BeiGene, Ltd (NASDAQ: BGNE)
Organization & Developments: Beigene
Parents
BeOne Medicines, formerly, BeiGene, Ltd (NASDAQ: BGNE)
Children
* Global impact: Expanding US and EU market share in BTK inhibitors underscores China’s ability to lead in major oncology categories.
*Brukinsa won FDA approval in CLL in 2023 following superior efficacy data vs ibrutinib in a head-to-head study.
*Global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines to improve treatment outcomes and expand access for patients worldwide
2017: BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO_Press Releases
2017: What Gilead Could Learn From Celgene - Gilead Sciences, Inc. (NASDAQ:GILD)
2018: BeiGene: A Promising Start To 2018 - BeiGene (NASDAQ:BGNE)
2018: Mirati Therapeutics_Revisiting A 'Busted IPO' Rocket_seekingalpha.com
2019: Amgen Is Taking A $2.7 Billion Stake In A Chinese Biotech — Beigene_Here's Whywww.investors.com
2020: Amgen doubles down on BeiGene investment as Chinese biotech aims to raise $2.1B
2020: BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals
2020: BeiGene_FiercePharma
2020: Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer
2022: BeiGene A Hold Despite Rapid Revenue Growth_seekingalpha.com
2024: BeiGene: Debating On Finally Establishing A Position_
2024: BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And U.S._seekingalpha.com
2024: BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
2025: BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
2025: BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025_ seekingalpha.com
2025: BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
2025: BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium
2025: ImmunityBio announces collaboration with Beigene_seekingalpha.com
2925: BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
Jumps
Finance & Acquisitions: Beigene
Key People: Beigene